首都医科大学附属北京佑安医院
Beijing Youan Hospital, Capital Medical University
在本站收录的 53 种疾病中,这家医院列在其中 7 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
首都医科大学附属北京佑安医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肝细胞癌Hepatocellular carcinoma67 篇牵头论文
- 骨肉瘤Osteosarcoma1 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
- 肝豆状核变性Wilson disease5 篇牵头论文
- 肝包虫病Hepatic echinococcosis0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis7 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 67 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 17 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- 分期
- I/II期
- 开始
- 2026-04
- 登记号
- NCT07479485
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、福州、郑州
- 正在招募Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- 分期
- 未注明
- 开始
- 2025-09
- 登记号
- NCT07170345
年龄 18 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州
- 正在招募NWRD06 DNA Plasmid for HCC After Curative Resection.
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07324304
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、哈尔滨、杭州
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文67
- Contrast-enhanced MRI for identifying the steatohepatitic hepatocellular carcinoma from small hepatocellular carcinoma.
- Machine Learning-Based Model for Predicting Recurrence-Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients.
- Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.
- Emerging roles of cuproptosis in liver diseases.
- Integrating single-cell RNA sequencing with spatial transcriptomics reveal the fibrosis-related genes in hepatocellular carcinoma.
- A prediction model based on machine learning: prognosis of HBV-induced HCC male patients with smoking and drinking habits after local ablation treatment.
- The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma.
- The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.
- Oral Chinese patent medicine combined with transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A Bayesian network meta-analysis.
- Immune Escape-Related Gene NXT1 as a Potential Prognostic and Therapeutic Target in Hepatocellular Carcinoma.
- The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients.
- Predictive Value of Preoperative Serum Substance P Levels for Post-Transplant Recurrence in Patients With Hepatocellular Carcinoma.
- A Novel Nomogram for Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
- Reduced muscle mass is an important part of Global Leadership Initiative on Malnutrition criteria in nutritional diagnosis of hepatocellular carcinoma.
- Immunotherapy for hepatocellular carcinoma.
- A Systematic Review and Meta-Analysis of MRI Radiomics for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma.
- Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study.
- Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study.
- Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score.
- Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis.
- Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.
- Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.
- Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process.
- HBx-induced upregulation of MAP1S drives hepatocellular carcinoma proliferation and migration via MAP1S/Smad/TGF-β1 loop.
- GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
- Diagnostic value of serum STIP1 in HCC and AFP-negative HCC.
- Relationship between STAP1 methylation in peripheral blood T cells and the clinicopathological characteristics and prognosis of patients within 5-cm diameter HCC.
- Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma.
- Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by SingleCell RNA Sequencing and its Implications for Prognosis and Therapeutic Response.
- Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence.
- Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network.
- CT radiomics for prediction of microvascular invasion in hepatocellular carcinoma: A systematic review and meta-analysis.
- Reprogramming of lipid metabolism in hepatocellular carcinoma resulting in downregulation of phosphatidylcholines used as potential markers for diagnosis and prediction.
- Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
- Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis.
- CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
- Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
- The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus.
- mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid.
- Dynamic Changes of Cytokine Profiles and Their Correlation With Tumor Recurrence Following Thermal Ablation in Hepatocellular Carcinoma.
- The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy.
- ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study.
- Knockout of ASPP2 promotes DEN-induced hepatocarcinogenesis via the NF-κB pathway in mice.
- Inactivation of tumor suppressor TAp63 by hepatitis B virus X protein in hepatocellular carcinoma.
- Digital Droplet PCR for Detection and Quantitation of Hepatitis Delta Virus.
- mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.
- Epidemic, risk factors of carbapenem-resistant Klebsiella pneumoniae infection and its effect on the early prognosis of liver transplantation.
- Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy.
- Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation.
- Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma.
- m7G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival.
- Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.
- Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma.
- AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R.
- Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China.
- Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
- Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
- Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma.
- Crosstalk between hepatic stellate cells and tumor cells in the development of hepatocellular carcinoma.
- Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.
- Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.
- Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.
- Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
- Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
- Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.
- Intracellular alpha-fetoprotein interferes with all-trans retinoic acid induced ATG7 expression and autophagy in hepatocellular carcinoma cells.
- Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
中文论文(未计入)10
- [Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].
- [Factors affecting tumorigenicity in liver cancer xenografts].
- [Advances in serological non-invasive diagnosis for metabolic dysfunction-associated fatty liver disease].
- [Exploration of cystathionine β-synthase and cystathionine γ-lyase gene expression poor prognostic predictive value with the application of bioinformatics data mining in liver cancer].
- [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
- [The study of a key molecule Caspase-1 of inflammasome in hepatitis B virus-related diseases].
- [Recommendations of EASL clinical practice guidelines on haemochromatosis].
- [Research progress in radiomics based on CT and MRI images for prediction of microvascular invasion in hepatocellular carcinoma].
- [Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
- [Study of the risk factors for recurrence of early and late stage hepatocellular carcinoma after hepatic artery embolization combined with radiofrequency ablation therapy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
- Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
- Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
- Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- NWRD06 DNA Plasmid for HCC After Curative Resection.
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 37 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
其他疾病
肝豆状核变性
Wilson disease2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07465718
年龄 8 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州
- 正在招募China Registry for Genetic / Metabolic Liver Diseases
- 分期
- 未注明
- 开始
- 2015-06
- 登记号
- NCT03131427
年龄未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Emerging roles of cuproptosis in liver diseases.
- Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets.
- The potential serum sphingolipid biomarkers for distinguishing Wilson disease.
- Wilson disease in pregnancy: A case series.
- Stem Cells Treatment for Wilson Disease.
中文论文(未计入)9
- [Recommendations from the European Association for the Study of the Liver and the European Reference Network for Rare Liver Diseases Clinical Practice Guidelines for hepatolenticular degeneration].
- [Progress on the research of hepatolenticular degeneration].
- [Inherited metabolic liver disease causing copper deposition].
- [Research progress of inherited metabolic liver disease in 2024].
- [Application of zinc agents in Wilson's disease].
- [An introduction to multidisciplinary recommendations for Wilson's disease comprehensive diagnosis and management: 2022 practice guidance from the American Association for the Study of Liver Diseases].
- [Interpretation of the 2022 edition guidelines for hepatolenticular degeneration diagnosis and treatment].
- [Management of hepatolenticular degeneration during pregnancy].
- [Research progress in gene therapy for Wilson's disease].
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在肝包虫病下全国有 44 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 15 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文7
- Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.
- Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.
- A new method to estimate the histological stage of primary biliary cholangitis.
- Ultrasound imaging findings in primary biliary cholangitis.
- Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.
- Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China.
- Disease predisposition of human leukocyte antigen class II genes influences the gut microbiota composition in patients with primary biliary cholangitis.
早期论文(2016–2020 年)5
- Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
- [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].
- Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis.
- [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].
- Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
联系这家医院
出示给工作人员或司机的院名卡
首都医科大学附属北京佑安医院
Beijing Youan Hospital, Capital Medical University
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Beijing Youan Hospital; Beijing You An Hospital; Capital Medical University affiliated Beijing You An Hospital; Beijing You An Hospital Affiliated to the Capital Medical University; Capital Medical University Affiliated Beijing Youan Hospital; Beijing YouAn Hospital Capital Medical University; Beijing Youan Hospital Affiliated with Capital Medical University; Beijing Youan Hospital of Capital Medical University